# 177Lu-DOTATATE for Recurrent Meningioma

> **NCT06326190** · PHASE2 · RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 136 (estimated)

## Conditions studied

- Recurrent Meningioma

## Interventions

- **DRUG:** Local standard of Care
- **DRUG:** 177Lu-DOTATATE

## Key facts

- **NCT ID:** NCT06326190
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2027-04-14
- **Final completion:** 2028-12-22
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06326190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06326190, "177Lu-DOTATATE for Recurrent Meningioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06326190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*